Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)

Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction; in most patients, these autoantibodies target acetylcholine receptors. MG is characterized by muscle weakness and fatigue. Acetylcholinesterase inhibitors (e.g., pyridostigmine), corticosteroids (e.g., prednisone), and short- and long-term immunosuppressants (e.g., mycophenolate mofetil, azathioprine) are the most prescribed agents to manage MG symptoms. Since the launch of eculizumab (Alexion / AstraZeneca’s Soliris) in 2017, a new wave of MG therapies with unique mechanisms of action are starting to affect the treatment landscape. The FDA approved efgartigimod (Argenx’s Vyvgart) in 2021 and its subcutaneous version in 2023, ravulizumab (Alexion / AstraZeneca’s Ultomiris) in 2022, and rozanolixizumab (UCB’s Rystiggo) and zilucoplan (UCB’s Zilbrysq) in 2023. As MG treatment continues to evolve, this report analyzes real-world claims data to uncover prescribing trends.

Questions answered

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed MG patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed MG patients?
• How have the new MG therapies been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of MG patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of MG patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key drugs: Soliris, Vyvgart, Ultomiris, Rystiggo, Zilbrysq, pyridostigmine

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.
• Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.